Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Katarína Timoracká"'
Autor:
Alena Kučerová, Petra Vágovičová, Jiří Vaněk, Renata Cifkova, Katarína Timoracká, Otto Mayer, Jan Filipovský, Václava Černá, Martin Pesta, Peter Wohlfahrt, Jitka Seidlerová, Jan Bruthans
Publikováno v:
Personalized Medicine. 12:463-473
Aim: We speculated whether DRD2 or CHRN subunit polymorphisms might be associated with the risk of smoking cessation failure in subjects after coronary heart disease (CHD) manifestation. Methods: A total of 964 patients with CHD, mean age 64.3 years
Autor:
Otto Mayer, Petra Vágovičová, Jiří Vaněk, Renata Cifkova, Jan Bruthans, Jan Filipovský, Peter Wohlfahrt, Katarína Timoracká, Jitka Seidlerová
Publikováno v:
Clinical Lipidology. 9:515-522
Aim: The definition of metabolic syndrome (MetSy) in patients with coronary heart disease (CHD) remains problematic because of concomitant treatment. We speculate, which definition is suitable in terms of long-term glycemic status. Methods: We analyz
Autor:
Jan Filipovský, Jan Bruthans, Renata Cifkova, Cees Vermeer, Otto Mayer, Elke Theuwissen, Lenka Černá, Jiří Vaněk, Katarína Timoracká, Peter Wohlfahrt, Jitka Seidlerová
Publikováno v:
Atherosclerosis, 235(1), 162-168. Elsevier Ireland Ltd
Background: Vitamin K is the essential co-factor for activation of matrix Gla-protein (MGP), the natural inhibitor of tissue calcification. Biologically inactive, desphospho-uncarboxylated MGP (dp-ucMGP) is a marker of vascular vitamin K status and i
Autor:
Cífková Renata, Jitka Seidlerová, Jiří Vaněk, Katarína Timoracká, Peter Wohlfahrt, Ladislav Trefil, Jan Bruthans, Lenka Černá, Otto Mayer, Jan Filipovský
Publikováno v:
European Journal of Internal Medicine. 25:556-560
Elevated lipoprotein-associated phospholipase A2 activity (aLp-PLA2) is associated with increased risk of cardiovascular events. In patients with stable atherovascular disease, we aimed to investigate whether impaired glucose metabolism might be asso
Autor:
Jan Filipovský, Věra Adámková, Petra Vágovičová, M. Galovcova, Otto Mayer, Katarína Timoracká, Jitka Seidlerová, Renata Cifkova, Jiří Vaněk, Jiří Bělohoubek, Jan Bruthans
Publikováno v:
Cor et Vasa. 56(2):e105-e112
IntroductionThe main objectives of cardiovascular prevention are to maintain risk factor management through lifestyle changes and use of cardioprotective medicines to reduce morbidity and mortality, and to improve quality of life.ObjectivesTo determi
Publikováno v:
Global Heart. 9:e125
Publikováno v:
Cor et Vasa. (2):e91-e97
Definite evidence has been established such that coronary patients benefit from appropriate secondary prevention. A series of EUROASPIRE surveys evaluated the level of implementation of coronary heart disease (CHD) prevention Guidelines. We aimed to